Alejandro Abia-De
Madrid, MD 28034, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.
Journal: Blood cancer discovery
Published: January 04, 2026
Apheresis CD8+CCR7+CD45RA- T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.
Journal: International journal of molecular sciences
Published: December 04, 2025
Comprehensive PHARmaceutical care programme in patients undergoing ALLOgeneic haematopoietic stem cell transplantation (PHARALLO): protocol for a prospective interventional study with a historical control group.
Journal: European journal of hospital pharmacy : science and practice
Published: November 04, 2025
Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).
Journal: Bone marrow transplantation
Published: October 02, 2025
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.
Journal: Bone marrow transplantation
Published: June 21, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.
Journal: Blood advances
Published: April 09, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.
Journal: British journal of haematology
Published: March 20, 2025
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.
Journal: Blood cancer discovery
Published: July 02, 2024
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.
Journal: Transplantation and cellular therapy
Published: May 10, 2024
Last Updated: 09/26/2026